ArticleBMC microbiology2024
Advancements in MRSA treatment: the role of berberine in enhancing antibiotic therapy.
Article in BMC microbiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Antibacterial Activity of Berberine AgainstBiology · 2026Article
- Emerging roles of combined curcumin and berberine in disease modulation: a comprehensive review of mechanisms and therapeutic relevance.Molecular biology reports · 2026Review
- Bridging traditional Chinese medicine theory with advanced MOFs delivery for synergistic drug-resistant infected-chronic wound therapy.Materials today. Bio · 2026Article
- Biosynthesis of benzylisoquinoline alkaloids and its evolution in plants.Plant communications · 2026Review
- Berberine as a therapeutic alkaloid against ESKAPE and multiple drug-resistant bacteria: a comprehensive review.Archives of microbiology · 2026Review
- Berberine as a therapeutic alkaloid against ESKAPE and multiple drug-resistant bacteria: a comprehensive review.Archives of microbiology · 2026Review
- Berberine modulates virulence gene expression in methicillin-resistantFrontiers in microbiology · 2026Article
- The Mechanism of Emodin Against Methicillin-ResistantLife (Basel, Switzerland) · 2025Article
- Network analysis of antimicrobial resistance inNAR genomics and bioinformatics · 2025Article
- Methicillin-ResistantAntibiotics (Basel, Switzerland) · 2025Review
- Mechanistic studies on the effect of berberine on methicillin-resistant Staphylococcus aureus drug resistance through modulation of wall teichoteic acid.Scientific reports · 2025Article
- Proteomics and acetyl-proteomics reveal the antibacterial mechanism of berberine sulfate against methicillin-resistantFrontiers in microbiology · 2025Article
- Progress in Research on Macrophage Polarization Mechanisms and Targeted Therapies inInfection and drug resistance · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundMethicillin-resistant Staphylococcus aureus (MRSA) is a significant public health problem. This study investigated the antimicrobial properties and mechanisms of berberine (BBR), a plant alkaloid, against MRSA, evaluating its potential to enhance antibiotic therapy.
resultsBerberine only demonstrated variable but significant inhibitory effects on 50 clinical MRSA strains. When combined with antibiotics, synergistic effects were observed only with amikacin in 6 of the 50 MRSA strains. BBR disrupted MRSA cell wall integrity, leading to leakage of cellular contents. Network pharmacology analysis revealed that BBR targets multiple pathways essential for bacterial survival.
conclusionThe study confirmed the potent antimicrobial activity of berberine against MRSA and its capability to act synergistically with traditional antibiotics. Berberine's impact on cell wall integrity and bacterial survival pathways highlights its potential as an adjunct therapy in MRSA treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.